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Background: Dual in-situ hybridization (DISH) assay is a relatively new assay for evaluating Human Epidermal
Growth Factor Receptor 2 (HER2) genomic amplification. Optimization protocol for the assay is not yet well
established, especially for archival tissues. Although there is a recommended nominal protocol, it is not suited for
formalin-fixed and paraffin-embedded (FFPE) samples that were archived for long periods.
Findings: In a study on local population of mucinous epithelial ovarian cancer, we developed a series of
optimization protocols based on the age of samples to improve success of the DISH assay. A decision workflow
was generated to facilitate individualization of further optimization protocols. The optimizations were evaluated on
92 whole tissue sections of FFPE mucinous ovarian tumors dating from 1990 to 2011. Overall, 79 samples were
successfully assayed for DISH using the series of optimization protocols. We found samples older than 1 year
required further optimization beyond the nominal protocol recommended. Thirteen samples were not further
assayed after first DISH assay due to inadequately preserved nuclear morphology with no ISH signals throughout
the tissue section.
Conclusion: The study revealed age of samples and storage conditions were major factors in successful DISH
assays. Samples that were ten years or less in age, and archived in-house were successfully optimized, whereas older
samples, which were also archived off-site, have a higher frequency of unsuccessful optimizations. The study
provides practical and important guidelines for the new DISH assay which can facilitate successful HER2 evaluation
in ovarian cancers and possibly other cancers as well.
Keywords: Dual in-situ hybridization, Fluorescence in-situ hybridization, Formalin-fixed paraffin-embedded tissue,
Human epidermal growth factor 2, Mucinous epithelial ovarian cancer, Optimization protocolsBackground
Fluorescence in-situ hybridization (FISH) assay has been
the gold standard in ascertainment of HER2 gene amplifi-
cation in breast and gastric cancers with well established
and proven protocols [1]. On the other hand, dual in-situ
hybridization (DISH) is a relatively new assay, approved
by the FDA in July 2011, with yet-to-be established
optimization protocols. Recent studies have shown both
assays are comparable in ovarian cancers [2,3]. FISH* Correspondence: liang.goh@duke-nus.edu.sg
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reproduction in any medium, provided the ortechnique requires time-sensitive interpretation, a need
for fluorescent microscope, and is more costly. In com-
parison, DISH assay is based on light microscopy; is more
user-friendly and the slides are archivable, hence proving
to be a more favorable option.
There is increasing evidence of significant HER2 gene
amplification in mucinous epithelial ovarian cancer
(mEOC), which is of great interest due to the potential
of targeted therapy such as Trastuzumab or Pertuzumab.
Of all epithelial ovarian cancer (EOC), mEOC is the least
studied due to their relative rarity. These cancers do not
respond well to chemotherapy and are associated with
poor prognosis [4,5]. Our previous study looking at copy
number alterations across four main histotypes of EOC
revealed mEOC harbored highest prevalence of HER2his is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of the samples that were used in this
study – the year of diagnosis, the number of samples in
each year, and the archival site are indicated
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gene for copy number alterations [6]. Several studies have
also shown high prevalence of HER2 in mEOC using im-
munohistochemistry (IHC) and in-situ hybridization as-
says. Mayr et al. [7] and McAlpine et al. [8] used IHC and
FISH to determine the prevalence of HER2 protein over-
expression and gene amplification. They reported 16.7%
and 18.2% of mEOC were HER2 positive in their western
cohorts (n = 17 and 33 respectively). In Yan et al. study
[3], IHC, FISH and DISH were employed on a small
Singapore cohort of samples (n = 17) dated from 2000 to
2010, reporting HER2 in 35.3% of mEOC. A recent large
western cohort study on 154 mEOC samples showed
18.8% of mEOC were HER2 positive [2].
In our study on HER2 in local patients using DISH
[9], we developed a series of optimization protocols and
a decision workflow for archived FFPE samples dating as
far back as 22 years. The establishment of these protocols
has facilitated our clinical research on ovarian cancers, in-
creasing success of the assay, especially for samples more
than 1 year old. We believe these protocols will add value
to others who utilize or intend to utilize DISH for HER2
ascertainment in ovarian cancers, and possibly other can-
cers such as breast and gastric cancers where HER2 is
prevalent. In ovarian cancers where HER2 inhibitor is not
yet incorporated in the treatment strategy, there is grow-
ing momentum to utilize HER2 inhibitor in treatment of
mucinous ovarian cancer [2]. Hence, the optimization
protocols may also be useful in clinical application, where
FFPE samples of current or recurrent cases need to be
reviewed for HER2 status.
Materials and methods
Patient specimens
Mucinous EOC cases (n = 92) diagnosed at KK Women’s
and Children’s Hospital (KKH), Singapore, between years
1990 and 2011 were included in this study. Details of the
patient specimens have been reported in another study
on HER2 and the clinicopathological factors that influ-
ence the disease [9]. Briefly, samples dated from year
2003 onwards were archived in KKH while those from
years 1990 to 2002 were archived off-site (Table 1). The
specimens were obtained from patients who underwent
unilateral or bilateral salpingo oophorectomy and/or total
hysterectomy, and were routinely fixed in neutral buffered
formalin (NBF) for variable durations. The histological
classification of mEOC was determined by gynaecological
pathologists at the time of diagnosis. Tissue specimens
were FFPE and 3 μm serial sections were used for
Hematoxylin and Eosin (H&E) staining to confirm the
presence of mEOC. The H&E slides were then reviewed
by the gynecological pathologist (SHC) who was involved
in the study and those which fulfilled the criteria of pri-
mary invasive mEOC were selected.Ethics
This study was approved by the institutional review
boards (IRB) of the National Cancer Centre Singapore,
KK Women's and Children's Hospital Singapore and
Singapore General Hospital Singapore. IRB waiver of
informed consent was approved as analyses were per-
formed retrospectively on non-identifiable data (CIRB
2010/425/B).
Dual in-situ hybridization
DISH was performed in an automated BenchMark ULTRA
(Ventana Medical Systems, USA) slide stainer, using the
INFORM HER2 Dual ISH DNA Probe Cocktail Assay
(Ventana Medical Systems, USA) that allows detection of
HER2 gene amplification by light microscopy.
A total of 92 mEOC samples were evaluated for HER2
gene amplification status. There are nine main steps to
the automated DISH – (i) baking to ensure adhesion of
tissue sections to the slide, (ii) deparaffinization to re-
move the paraffin for reagent penetration, (iii) pretreat-
ment to open protein crosslinks and expose nucleic
acids, (iv) denaturation of double stranded DNA to
expose the DNA targets, (v) hybridization of probes to
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probes, (vii) indirect detection of hybridization event,
(viii) counterstaining to enhance visualization, and (ix)
coverslipping to protect the tissue sections.
The DISH protocol has been previously described [10].
Briefly, tissue sections were deparaffinized and pre-
treated with Cell Conditioning 2 (CC2) at pH 6 at 86°C.
Enzymatic digestion of proteins was performed with ISH
protease 2 or 3 for variable length of time. The double-
stranded DNA was denatured, allowing hybridization of
labeled probes - dinitrophenyl (DNP)-labeled HER2 DNA
probe to the HER2 gene and digoxigenin (DIG)-labeled
Chromosome 17 centromere probe (CEN17) to the
centromere of chromosome 17. A stringency wash was
performed at 72°C using sodium citrate, sodium chloride
(SSC 10×) to wash off unbound or weakly bound probes.
The ultraView Silver ISH DNP and ultraView Red ISH
DIG detection kits (Ventana Medical Systems, USA) were
used for the detection of HER2 and CEN17 signals re-
spectively. For detection of HER2 gene, the slides were
first incubated with rabbit anti-DNP antibodies, followed
by horse radish peroxidase (HRP)-conjugated goat anti-
rabbit antibodies. Reaction of Silver ISH DNP Chromo-
gens A, B and C with HRP will produce black signals
which represent the HER2 gene. For detection of CEN17
signals, the slides were first incubated with mouse anti-
DIG antibodies, followed by alkaline phosphatase (AP)-
conjugated goat anti-mouse antibodies. The substrates for
AP were Red ISH DIG pH enhancer, naphthol and Fast
Red. The enzymatic reaction will result in red signals
which represent the centromere of chromosome 17. Tis-
sue sections were then counterstained in hematoxylin II
and bluing reagent to enhance contrast. To minimize
evaporation of aqueous reagents from the slides, liquid
coverslip (LCS) was applied to the tissue sections by the
stainer. Upon completion, slides were unloaded. Tissue
sections were soaked in a detergent bath to wash off LCS,
followed by soaking in a water bath to rinse off the deter-
gent. Tissue sections were then baked in an oven at 55°C
for 30 minutes to dry the tissue sections before coverslip-
ping was done in Cytoseal 60 mounting media (Richard
Allan Scientific, USA). The expected outcome from the
slides was optimal staining, i.e. distinct nuclear morph-
ology without obscuration of the red and black signals,
and without non-specific background staining. This is to
ensure specificity in the enumeration of the red and black
signals within each nucleus. For slides without optimal
staining, further optimizations protocols were needed.
Development of optimization protocols
DISH is a newly established in-situ hybridization assay
and the parameters in the nominal protocol (U1) were
developed for samples that are freshly fixed in formalin
and embedded in paraffin, and not entirely applicablefor the older samples. Therefore, optimization of the
protocol parameters had to be performed in older samples
to promote optimal staining. In general, six parameters
were explored during optimization: (i) incubation times of
the three cycles of CC2, (ii) use of either ISH proteases 2
or 3, and their incubation times, (iii) temperature of strin-
gency wash, (iv) incubation times of SISH and Red ISH
multimers, (v) incubation times of silver and red chromo-
gens, (vi) incubation times of Hematoxylin II and bluing
reagent. In some instances, subsequent individualized
optimization was done to improve signals visualization.Findings
DISH optimization protocols
Table 1 summarizes the samples used in this study, and
their archived location. Ninety two mEOC samples were
evaluated with DISH, of which 79 samples were success-
fully optimized using a series of optimization protocols
developed for this study. Table 2 lists the nominal proto-
col U1 and four other protocols (U2, U3, U4 and U5)
which had parameters modified from U1. All protocol
numbers were arbitrarily assigned. In developing the
four other protocols (U2, U3, U4 and U5), age of sam-
ples was a major consideration during the optimization
of parameters from the nominal protocol (U1) for pro-
tocols U2, U3, U4 and U5. In general, U1 (nominal
protocol) was used for the most recent year 2011 sam-
ples on hand, U2 protocol for samples dated between
year 2008 and 2010, U3 for samples dated between 2003
and 2007, U4 for samples dated between 2000 and 2002,
and U5 for samples dated in the 1990s. Several parame-
ters in the nominal protocol were explored. The follow-
ing sections describe the reasoning for altering the
nominal parameters.Cell conditioning 2
With increasing age of samples, stronger pre-treatment
of the tissue sections was applied, by increasing the in-
cubation periods of CC2 and/or ISH proteases. The ultra
CC2 solution is a citrate buffer at pH 6. It functions to
break covalent protein-protein and protein-DNA cross-
links that were formed by formalin in the tissue. The
breakage of the bonds is done in conjunction with the
heating mechanism on each slide pad. The heat serves
to increase the kinetic energy of the molecules that are
found in the sample, and the increased motion will cause
the bonds that were formed during fixation to break. Re-
moving these bonds would aid in unmasking of the tar-
get DNA for hybridization to occur. By increasing the
incubation times of the three cycles of CC2 treatment,
there is increased probability that the bonds will be
broken.
Table 2 Nominal and optimization protocols for Dual in-situ hybridization (DISH)
Selectable parameters U1 (Nominal
protocol)
U2 U3 U4 U5
Year of samples 2011 2008-2010 2003-2007 2000-2002 1990s
Baking temperature 63°C 63°C 63°C 63°C 63°C
Baking time 20 mins 20 mins 20 mins 20 mins 20 mins
Deparaffinization 72°C 72°C 72°C 72°C 72°C
Extended deparaffinization Not selected Not selected Not selected Not selected Not selected
Cell conditioning duration 3 cycles of CC2
at 86°C
3 cycles of CC2
at 86°C
3 cycles of CC2
at 86°C
3 cycles of CC2
at 86°C

























ISH protease – 2 or 3, and
duration
ISH protease 3 ISH protease 2 ISH protease 2 ISH protease 2 ISH protease2
−16 mins −8 mins −8 mins −8 mins −12 mins
Denaturation time 20 mins 20 mins 20 mins 20 mins 20 mins
Hybridization time 6 hours 6 hours 6 hours 6 hours 6 hours
Stringency wash temperature 72°C 72°C 72°C 72°C 76°C
SISH multimer incubation time 32 mins 36 mins 36 mins 36 mins 36 mins
Silver chromogen incubation
time
4 mins 8 mins 8 mins 8 mins 8 mins
Red ISH multimer incubation time 24 mins 28 mins 28 mins 28 mins 28 mins
Red chromogen incubation time 8 mins 12 mins 12 mins 12 mins 12 mins
Hematoxylin II incubation time 8 mins 8 mins 12 mins 12 mins 12 mins
Bluing reagent incubation time 4 mins 4 mins 8 mins 8 mins 8 mins
CC2: Cell Conditioning 2. Parameters highlighted in bold indicate changes from nominal protocol U1.
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Both ISH proteases 2 and 3 serve the same function – they
permeabilize cell membranes as the DNA of interest is
found intracellularly. It also cleaves peptide bonds of
proteins that surround the DNA of interest. The reason
for using ISH protease 2 is because it has stronger protease
activity in alkaline pH, compared to ISH protease 3.
Multimers and chromogens
By increasing the incubation time of SISH and Red ISH
multimers which are secondary antibodies conjugated
with horse radish peroxidase and alkaline phosphatase
respectively, there is more time for the secondary
antibodies to bind to their respective primary antibodies.
Increasing the detection component (i.e. chromogens)
incubation times is effective for controlling signal size
and/or intensity. This will aid in signal enhancement.
Hematoxylin II and bluing reagent
The incubation times of Hematoxylin II and bluing re-
agent were increased in U3, U4 and U5 protocols in the
hope that the nuclear morphology would be more easilydistinguished by enhancing the blue color within the nu-
cleus. This is because from U3 protocol onwards, there
is increased duration of cell conditioning given to the
tissue sections. This may cause excessive breakage of the
covalent protein-protein and protein-DNA crosslinks in
the tissue, therefore causing the nuclear morphology to
be less distinguishable.
Decision workflow for optimization
Figure 1 shows the decision tree that was developed to
facilitate the workflow in subsequent individualized
optimization. Five main problems were observed upon
first DISH optimization (using either of U1, U2, U3, U4
or U5) and highlighted in the workflow. They include:
absence of ISH signals with preserved nuclear morph-
ology, presence of non-specific background staining
(SISH dust and red haze), strong or weak counterstain,
presence of nuclear bubbling, and fuzzy ISH signals. Be-
sides changing the parameters for CC2, ISH proteases,
SISH and Red ISH multimers, red and silver chromo-
gens, and Hematoxylin II and bluing reagent according
to the problems observed, selection of extended
Figure 1 Decision workflow for optimizing DISH protocols. Potential problems with corresponding protocols are highlighted in the
decision tree.
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gency wash were also done in the subsequent individual-
ized optimization, if necessary.
Extended deparaffinization was selected when nuclear
bubbling occurred. This happened as a result of excess
paraffin in the tissue section. Temperature of stringency
wash were increased from 72°C to 76°C if the red signals
appeared fuzzy i.e. not a solid and discrete red signal. In-
cubation duration of counterstains were adjusted for if
the nuclear counterstain was too light/dark. Visibility of
nuclear boundary might be a problem if the counterstain
was light, and obscuration of black signals might occur
if the counterstain was too dark. When non-specific
background staining like SISH dust and red haze oc-
curred, the incubation times for SISH multimer and silver
chromogen, and Red ISH multimer and red chromogen
was decreased.
Individualized optimization
Despite optimization protocols for the samples dated be-
tween 1990 and 2010, some samples had to beindividually optimized subsequently, depending on the
type of problems seen upon first DISH assessment when
the respective protocols were applied in accordance to
the year of the sample. Figure 2A shows a sample dated
year 2003 for which protocol U3 was applied. However,
there were no visible red and black signals within the
nuclei. A second round of optimization was performed –
several parameters in U3 were modified into a new
protocol U6. As there were no red and black signals,
longer cell conditioning and stronger protease treatment
were given, according to the decision workflow in Figure 1.
ISH protease 2, which is an alkaline protease of higher
strength than ISH protease 3, was already used in the first
DISH testing. However, there were no signals. Thus the
incubation time for ISH protease 2 was increased from
eight minutes to 12 minutes. The duration of three cycles
of cell conditioning by CC2 was also increased from 12
minutes to 16 minutes so that there would be sufficient
time for CC2 to break covalent protein-protein and
protein-DNA crosslinks formed by formalin. This would
also aid in unmasking the target DNA. Since there was
Figure 2 Results of DISH before and after individualized optimization for a sample from year 2003. (A) U3 protocol was used for first
DISH analysis. There were no red and black signals within the nuclei, and there was SISH dust in the background. As the nuclear morphology was
preserved, further optimization could be done to optimize the staining process. (B) U6 protocol was used for the second DISH analysis and was
successful. There were enumerable red and black signals within the nuclei after a longer duration of cell conditioning with CC2 and longer ISH
protease 2 treatments were used. The lengths of incubation for SISH and Red ISH multimers, silver and red ISH chromogens, Hematoxylin II
counterstain and bluing reagent were decreased so as to reduce unspecific background staining (SISH dust) and intensity of counterstain.
Original magnification (A, B: 600×).
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silver chromogen was decreased to 32 and four minutes
respectively so as to reduce non-specific background
staining. Because increased duration of protease treatment
would create more non-specific background staining due
to unmasking of more non-specific DNA, the incubation
periods of the Red ISH multimer and red chromogen have
to be decreased as well, to 24 and eight minutes respect-
ively. As the counterstain was dark with U3 protocol,Table 3 Individualized optimization (U6): protocol used for o
protocol U3
Selectable parameters Protocol used for first DISH
Baking temperature 63°C
Baking time 20 mins
Deparaffinization 72°C
Extended deparaffinization Not selected
Cell conditioning duration 3 cycles of cell conditioning 2
Mild CC2: 12 min
Standard CC2: 12 m
Extended CC2: 12 m
ISH protease – 2 or 3, and duration ISH protease 2 – 8 m
Denaturation time 20 mins
Hybridization time 6 hours
Stringency wash temperature 72°C
SISH multimer incubation time 36 mins
Silver chromogen incubation time 8 mins
Red ISH multimer incubation time 28 mins
Red chromogen incubation time 12 mins
Hematoxylin II incubation time 12 mins
Bluing reagent incubation time 8 mins
The incubation lengths of various selectable parameters that were changed are in bincubation periods for hematoxylin II and bluing reagent
were also decreased to eight and four minutes respectively
so that SISH signals will not be obscured. Figure 2B shows
the optimal results achieved with subsequent optimization.
Table 3 summarized the modified protocol.
Unsuccessful optimization
During the first DISH assessment, 13 samples showed
inadequately preserved nuclear morphology with no ISHptimization of a 2003 case and comparison with first DISH
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timized, and were deemed as unsuccessfully optimized.
Optimization was not done for the reason that in order to
accentuate the red and black signals, longer cell condition-
ing and harsher protease treatment had to be given. This
would in turn cause poorer nuclear morphology which
would affect signal enumeration.
Effects of age of samples on DISH
Age of samples is a factor that was considered during
the design of optimization protocols. Samples more than
1 year old needed optimization beyond the nominal
protocol. Figure 3A shows the numbers of successful
and unsuccessful optimization for the 92 samples. Suc-
cessful optimizations were achieved for samples dated
from year 2003 onwards, regardless of the number of
optimizations required. Optimization failures occurred in
samples dated before year 2003 which were also those that
were archived off-site, as shown in Table 1. Figure 3B
shows cumulative percentage of samples with unsuccess-
ful optimization, providing us with a means for deciding
future DISH assay based on: (i) age of samples, and (ii) tol-
erance for unsuccessful optimizations. For example, the
plot indicates that for successful DISH experiments (i.e.
zero unsuccessful optimization), samples from 2003 on-
wards (i.e. ≤ 10 years) could be used. These samples were
also archived within KKH. Optimization failure happens
to samples which were archived off-site and they were also
more than 10 years of age. Storage conditions have been
shown to be a factor in determining quality of the samplesFigure 3 Effects of age of samples on optimizations. (A) Number of un
were not successfully optimized. All samples dated between 2003 and 201
observed in 1990, 1995 and 2000. There was 1 unsuccessful optimization in
optimizations in 1994. The most number of samples that were not optimiz
unsuccessfully optimized.[11-15] which will affect success of DISH assay. In our la-
boratory archival protocol, samples more than 10 years
old in general, were archived off-site. Figure 3A showed
samples that were archived off-site, at least 50% from each
year could still be optimized successfully. Overall, 76.8%
samples archived off-site succeeded in the DISH assay
using the optimization protocols. We find Figure 3B
useful as a guideline to determine tolerance for failure
in optimization, especially when resources are limited.
In the case where 5% of samples were allowed to fail
optimization, the plot indicates that samples dating
from year 2000 onwards could be considered. It should
be noted that the analysis shown in Figure 3B is specific
to our local context, though the method could be
employed in other DISH studies to establish guidelines
applicable for their particular environment.
Discussion
The study explored several parameters in the nominal
protocol and formulated a series of optimization proto-
cols and decision workflow for successful DISH assay.
Age of samples was a major consideration in the process
of developing optimization protocols. Our objective was
to improve decision making in choosing of optimization
protocols, especially critical when tissue samples are of
limited quantity. The workflow in Figure 1 provides a
roadmap, covering majority of problems encountered
with the assay in older samples. Complications that may
arise when staining are non-optimal are: (i) overesti-
mation of the number of red and/or black signals due tosuccessful optimizations from 1990 to 2011. A total of 13 samples
1 were optimized successfully. No unsuccessful optimization was
years 1991, 1992, 1993, 1996, 1997, 2001 and 2002; 2 unsuccessful
ed successfully is from year 1998. (B) Cumulative % of samples
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red and/or black signals due to non-distinct nuclear
morphology (bigger nucleus envisioned), or we may
underestimate the number of signals (smaller nucleus
envisioned). It should be noted the optimization proto-
cols (U2 to U5) was not tested on the more recent
fresher samples due to limited amount of tissue samples.
In general, we recommend U1 for the fresher samples
while U2-U5 would be more applicable for problems ob-
served in older samples.
The study also highlights possible reasons for unsuc-
cessful optimization in older samples, including long
archival period and impact of storage conditions of FFPE
samples which has been previously reported [11-16]. It
showed samples which were archived off-site had a higher
proportion of unsuccessful optimizations, as compared to
those samples archived at KKH (Table 1). Since age of
samples is confounded with off-site storage in this study,
we could not tease out individual effects of these two fac-
tors. We like to highlight that effects of samples quality
tend to be less detrimental on IHC, which was what we
observed in this study. For samples that failed DISH, we
were able to observe staining using IHC.
Other factors affecting the assay include the temperature
at which the FFPE samples were archived at, whether they
were protected from the air or sunlight, duration of stor-
age, and tissue fixation [16-19]. The tissue fixation and
embedding process, as well as the archival of these FFPE
blocks for extended period of time, have a negative influ-
ence on the quality of DNA and RNA quality [14]. Storage
of FFPE samples at 4°C has been shown to yield the best
result; there is minimal fragmentation of the nucleic acid
[14]. DNA fragmentation also occurs gradually overtime
therefore DNA quality in samples that were archived for
longer periods were affected [15]. In addition, exposure to
air or sunlight has a negative influence on the quality of
the nucleic acid.
Tissue fixation factors such as type of fixative used,
cold ischemia time, and fixation time, can also affect
optimal staining. At the time of the study, it was not
possible to obtain information on the fixation protocols
of past years in KKH. However, neutral-buffered forma-
lin (NBF) has been routinely used in KKH over the
years. In general, for INFORM HER2 Dual ISH DNA
Probe Cocktail Assay to work optimally it was recom-
mended that tissues are fixed in NBF for six to 48 hours;
this is consistent with the HER2 testing guidelines estab-
lished by ASCO/CAP [17]. NBF has been routinely used
in KKH but fixation time was not controlled for. The
thickness of the tissue will determine the length of time
for fixation as fixative penetration into the tissue is a
rate-limiting step. Penetration rates decrease with depth.
Larger samples would require a longer fixation time, to
allow formalin to penetrate the tissue [12]. Diffusion offormalin into the tissue is also taken into consideration
for fixation time [11]. Therefore, if insufficient time
(< 6 hours) was given for fixation, tissues may be inad-
equately fixed in the center of the sample. This appeared
to be the case for some of the samples where good nu-
clear morphology with optimal signals and adequate
counterstain were observed at the periphery but poor
nuclear morphology without any signals in the center.
This is because the center of the tissue has undergone
tissue autolysis whereby nucleic acids are degraded by
the endogenous nucleases [14]. In order to reduce tissue
autolysis, one recommendation is to keep the thickness
of the sample at 5 mm so as to ensure an even fixation
throughout the sample. Samples that undergo autolysis
have a loss in hybridization capability [12]. Unsuccessful
optimization could also be due to over-fixation of tissues
(>48 hours) which causes an increased number of irre-
versible crosslinks [11,14]. The time from which the sam-
ple is removed from the patient to the time of fixation
which is also known as cold ischemia time, is also crucial
to successful DISH analysis. Ideally, it should be < 1 hour,
according to ASCO/CAP guidelines [18]. The time to fix-
ation is of utmost importance because cellular processes
and tissue autolysis can take place during this time inter-
val [14]. If the time between sample collection and fixation
is shortened, DNA quality will be improved [12]. There-
fore, it is important that after collection, samples are
sent immediately to the histopathology laboratory for
processing [12].
DISH assay has been introduced as an alternative to
FISH in the evaluation of HER2 gene amplification.
Although FISH has been the gold standard for HER2
evaluation in cancers, it has several limitations. This in-
cludes inability to visualize nuclear morphology for dif-
ferentiation of tumor tissue and normal tissue during
signal enumeration; fading of fluorescent signals over
time resulting in the inability to archive, and high cost
[1,17,19]. It also requires expertise and fluorescence im-
aging system for interpretation [1,19]. Both FISH and DISH
techniques are based on the principle of hybridization of
probes to their target sequences, i.e. the HER2 gene as well
as the alpha satellite repeats in the centromere of chromo-
some 17 [20]. However, DISH and FISH differ in their
detection due to the different probe labeling method. In
FISH, the probes are labeled with fluorophores and thus de-
tected fluorescently. In DISH, the probes are labeled with
haptens which can be detected under light microscope.
DISH is a combination of silver in-situ hybridization
(SISH) and red in-situ hybridization (Red ISH), and it en-
ables visible nuclear morphology allowing differentiation
of normal and tumor tissue in conjunction with HER2
gene amplification status. Interpretation is based on light
microscopy which is more user-friendly and the slides are
archivable.
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This study developed an optimization decision workflow
and a series of optimization protocols for DISH assay. It
highlighted the potential problems that can be encoun-
tered in DISH and recommends alterations in six pri-
mary parameters: CC2, ISH protease, temperature of
stringency wash, SISH and ISH multimers, silver and red
chromogens, and Hematoxylin II and bluing reagent to
improve success of the assay. In instances when the first
round of optimization was unsuccessful (i.e. no visible
signals with preserved nuclear morphology), stronger pre-
treatment were given to enhance signals. Also, if other
problems surfaced during the first round of optimization,
parameters were altered consequently. A decision work-
flow has been developed to provide guidelines on this.
Overall, the major factors affecting the success of DISH
are age of samples and storage conditions. Samples more
than 10 years and archived off-site tend to show more fail-
ures in optimization.
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